Leerink Partners Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7

Leerink Partners analyst Jeffrey La Rosa maintains Pyxis Oncology (NASDAQ: PYXS ) with a Outperform and lowers the price target from $9 to $7.